Cutia Therapeutics (2487) AI Stock Analysis

• Market Cap: HK$2.74B
• Dividend Yield: N/A
• Average Volume (3M): 998.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: 101.58%
• EPS Growth: 78.88%
• Country: HK
• Employees: 333
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.80
• Shares Outstanding: 320,829,100
• 10 Day Avg. Volume: 864,912
• 30 Day Avg. Volume: 998,797
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: HK$8.50 ▼(-0.58% Downside)

Cutia Therapeutics faces significant challenges with profitability and cash flow, impacting its financial performance score. Technical analysis indicates weak momentum, and the valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score.

Cutia Therapeutics Business Overview & Revenue Model

Company Description

Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases. The company focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company was incorporated in 2019 and is based in Shanghai, China with additional offices in Beijing, Wuxi and Hong Kong.

How the Company Makes Money

Cutia Therapeutics generates revenue through multiple streams primarily centered around the commercialization of its therapeutic products. The company earns income from the sale of its approved medications to healthcare providers and institutions. Additionally, Cutia engages in strategic partnerships and collaborations with larger pharmaceutical companies, which can provide upfront licensing fees, milestone payments based on product development progress, and royalties on future sales. Research grants and funding from government and private entities also contribute to its revenue, enabling further innovation and expansion of its product pipeline.

Cutia Therapeutics Financial Statement Overview

Summary

Cutia Therapeutics demonstrates strong revenue growth, indicating potential for market expansion. However, persistent negative EBIT and net income highlight profitability challenges. The balance sheet is solid with adequate equity, but negative cash flows raise sustainability concerns.

Income Statement

Cutia Therapeutics has shown strong revenue growth, increasing from HK$2.03 million in 2021 to HK$279.62 million in 2024, indicating a solid growth trajectory. However, the company is experiencing continued negative EBIT and net income, reflecting ongoing profitability challenges. The gross profit margin remains strong, suggesting efficient production but is overshadowed by high operational costs.

Balance Sheet

The company exhibits a healthy equity ratio due to substantial stockholders' equity relative to total assets. However, there is a significant concern with profitability as net income remains negative, impacting return on equity. The debt-to-equity ratio suggests a moderate level of financial leverage, which is manageable but requires monitoring given the negative earnings.

Cash Flow

Operating and free cash flows are negative, indicating potential cash management issues and sustainability concerns. The absence of growth in free cash flow suggests ongoing operational challenges. The company needs to improve cash flow management to ensure long-term viability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	279.62M	137.62M	11.37M	2.04M
Gross Profit	143.46M	71.01M	7.94M	1.61M
EBITDA	-430.69M	-1.92B	-535.19M	-309.23M
Net Income	-433.81M	-1.96B	-555.84M	-319.58M
Balance Sheet
Total Assets	1.39B	1.71B	1.45B	1.49B
Cash, Cash Equivalents and Short-Term Investments	876.15M	1.27B	1.08B	1.38B
Total Debt	320.94M	243.75M	54.13M	26.53M
Total Liabilities	418.51M	357.76M	2.69B	2.29B
Stockholders Equity	974.73M	1.35B	-1.25B	-790.51M
Cash Flow
Free Cash Flow	-468.66M	-437.23M	-371.50M	-185.76M
Operating Cash Flow	-442.98M	-381.31M	-236.19M	-159.88M
Investing Cash Flow	316.07M	-203.58M	462.06M	-410.65M
Financing Cash Flow	37.84M	588.32M	-10.25M	480.76M

Cutia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.55
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2487, the sentiment is Negative. The current price of 8.55 is below the 20-day moving average (MA) of 9.19, below the 50-day MA of 9.69, and above the 200-day MA of 7.58, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 42.23 is Neutral, neither overbought nor oversold. The STOCH value of 47.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2487.

Cutia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1873	63 Neutral	HK$3.91B	21.92	4.47%	―	-9.75%	―
3681	52 Neutral	HK$3.45B	―	-75.64%	―	42.21%	29.52%
1167	50 Neutral	HK$5.75B	―	-15.59%	―	139.04%	57.13%
2616	49 Neutral	HK$10.09B	―	-22.23%	―	-14.17%	76.00%
Sector *	47 Neutral	C$190.13M	-2.29	-23.77%	3.17%	17.53%	1.84%
2487	44 Neutral	HK$2.74B	―	-37.29%	―	101.58%	78.88%
2179	42 Neutral	HK$3.63B	―	-69.97%	―	―	3.30%

Cutia Therapeutics Corporate Events

Cutia Therapeutics Gains Hong Kong Approval for Topical Finasteride Spray

Cutia Therapeutics has announced that its topical finasteride spray, CU-40102, has received marketing approval from the Hong Kong Department of Health for the treatment of androgenetic alopecia. This approval marks a significant milestone for the company, following previous approval by China’s National Medical Products Administration. The topical formulation of CU-40102 is designed to reduce systemic exposure compared to oral versions, potentially making it more appealing to patients. This approval is expected to accelerate the product’s global expansion and broaden its market reach, benefiting more patients with androgenetic alopecia.

Cutia Therapeutics Gains Approval for Innovative Hair Loss Treatment in China

Cutia Therapeutics announced that its topical finasteride spray, CU-40102, has received marketing approval from China’s National Medical Products Administration for the treatment of androgenetic alopecia. This approval marks the first global and Chinese approval for a topical finasteride product, enhancing Cutia’s position in the dermatology sector. The product’s approval is based on successful Phase III clinical trials in China, and it represents a significant step in expanding the company’s product offerings in scalp care. A New Drug Application has also been submitted in Hong Kong, furthering its market reach.

Cutia Therapeutics’ Phase III Trial Results for CU-30101 Accepted for Presentation

Cutia Therapeutics announced that its Phase III clinical trial results for CU-30101, a localized topical lidocaine and tetracaine cream, were accepted for presentation at the 30th Annual Meeting of the Chinese Society of Dermatology. The trial demonstrated that CU-30101 is as effective as the reference product, Pliaglis®, in providing analgesia with a favorable safety profile, leading to the submission of a marketing authorization application to the National Medical Products Administration.

Cutia Therapeutics Successfully Passes All Resolutions at AGM

Cutia Therapeutics held its Annual General Meeting on June 5, 2025, where all proposed resolutions were passed by poll. Key resolutions included the re-election of directors, reappointment of auditors, and granting of mandates to repurchase and issue shares, indicating strong shareholder support and strategic positioning for future growth.